Fischer Medical Ventures Ltd · NSE:FISCHER

Fischer Medical Ventures — Investor Presentation (September 2026)

39 slides from Fischer Medical Ventures's investor presentation, Sep 17, 2026

  1. Slide 1: Submission of revised presentation to exchanges

    FISCHER MEDICAL VENTURES LIMITED Registered Office Address: Survey No. 480/2 AP Medtech Zone, Nadupura Village, Pedagantyadu Mandal, Visakhapatnam, 530032 CIN: L86900AP1993PLC118162 Email: cs@fischermv.com | Website: www.fischermv.com | Contact 9080966548 September 17, 2026 To To BSE Limited Nationa

  2. Slide 2: Investor & Strategic Partnership Presentation

    INVESTOR & STRATEGIC PARTNERSHIP PRESENTATION Fischer Medical Ventures Limited Building the world's largest Healthcare Al Solutions Platform Al-enabled Medical Imaging I Population-scale Screening I Hospital Digitization June 2026 Confidential I Do Not Distribute

  3. Slide 3: Disclaimer

    ■ LEGAL NOTICE Disclaimer Information Memorandum prepared for Fischer Medical Ventures Limited I PREPARED BY Fischer Medical Ventures • Purpose & Scope • Due Diligence & Risk Acknowledgement Potential investors and strategic partners are advised to perform their own due diligence and consult The inf

  4. Slide 4: FMV Executive Summary

    BB Executive overRvVIEW \ <a FMV - Executive Summary An integrated Al-enabled healthcare platform spanning imaging, screening, digitization and analytics 02] Medical Imaging Leadership 02 } Al Healthcare Ecosystem © Screening & Prevention Comprehensive MRI, CT, X-Ray & Mammography portfolio with pro

  5. Slide 5: Strategic Ecosystem — FMV, Time Medical & FlynnCare

    Bi croup RELATIONSHIPS Lr Strategic Ecosystem — FMV, Time Medical & FlynnCare How the three operating brands combine into one integrated healthcare innovation engine TIME MEDICAL Ws FMV ea FlynnCare fr. fiCar International Ventures Fischer Medical Ventures Health Innovations TECHNOLOGY FOUNDATION CO

  6. Slide 6: Vision & Mission

    BB STRATEGIC INTENT 4 Vision & Mission Reimagining healthcare through Al-enabled early detection and access CG Mission To make early detection and preventive healthcare To deploy Al-enabled diagnostic and screening universally accessible through intelligent, integrated platforms that digitize health

  7. Slide 7: Our Journey So Far

    Hi company JOURNEY 4 Our Journey So Far From R&D origins to a publicly-listed integrated healthcare Al platform 2008 2012 2021 2024 Foundation FDA/CE Manufacturing NSE Listing R&D in US, China, HK. IP from . R&D + manufacturing. Rights across Listed on NSE. Strong order book. Columbia & Harvard. PIG

  8. Slide 8: Three Strategic Imaging Pillars

    Hi iMaAGine PortFolio Lr Three Strategic Imaging Pillars @ TIME MEDICAL International Ventures Diagnostics, screening and interventional radiology under one platform ‘A Wholly Owned Subsidiary of A Fischer PILLAR O1 PILLAR O02 PILLAR 03 Diagnostics Screening Interventional Radiology Cd @ wri @ Vega

  9. Slide 9: Proprietary Technology Stack

    ■ DISRUPTIVE TECHNOLOGIES Proprietary Technology Stack • ���n�ti���!�!s L Six pillars powering best-in-class imaging performance A Wholly Owned Subsidiary of/' EJ!£!!!!! 0■ Magnet Technology Permanent & LTS 0.35T/ 0 ■ RF Coil Technology Multi-channel phased array 0 ■ Console Technology Unified scann

  10. Slide 10: FMV List of Directors

    DIRECTORS FMV List of Directors Board of Directors Chairman & Managing Director Whole Time Director Independent Director Ravindran Govindan Svetlana Rao Raviwada Khairy Jamaluddin Abu Bakar • Electronics & Communications Engineer with prior • Former Chairman & President (APAC), Fisher Scientific • F

  11. Slide 11: FMV List of Directors

    DIRECTORS FMV List of Directors Board of Directors Independent Director Independent Director Independent Director Ms. Jaya Ankur Singhania Mr. Richard Chan Sing En Dr. Syed Jalaluddin • 15+ years in corporate governance and legal advisory • 30+ years in private equity and corporate finance • Disting

  12. Slide 12: Key Managerial Personnel — FMV Group

    ■ DIRECTORS FMVKMP Key Managerial Personal- FMV Group FMV Group Chief Operating FMV Group Chief Financial Chief Technology Officer- Time Chief Operating Officer- Time Medical Officer Officer Medical Shankar Varadharajan Vivek Balasubramanian Simon Yeung Amol Mhaskar • 30+ years in investment • Chart

  13. Slide 13: Key Managerial Personnel — FMV Group

    By Directors 4 FMV KMP Key Managerial Personal- FMV Group Chief Technology Officer- Flynncare Chief Solutions Architect - Flynncare VP- Plant Operations- Time Medical (. Alagaraja Ravindra Raja Karthikeyan R Commander Yogendra Sharma = Alagaraja has more 20 years of = With over 19 years of professio

  14. Slide 14: MRI Diagnostic Range

    Bp mri portFotio MRI Diagnostic Range Six platform families covering open, closed-bore and ultra-high field segments PICA /PANION/ — AURA —- ae Ss : SS “Sh Open architecture, pediatric, weight-bearing MICA / MICA Smart “i xe General-purpose, high performance Approvals: FDA / CE /CDSCO Approvals: CDS

  15. Slide 15: Open Architecture MRI Solutions

    BB OPEN ARCHITECTURE 4 La Open Architecture MRI Solutions @ TIME MEDICAL International Ventures PICA 0.35T and AURA 0.7T — comfort, accessibility and cost-effectiveness Wholly Owned Subsidiary of AY Fischer PICA 0.35T AURA 0.7T =" Open architecture design sey __ = Best-in-class patient —_— = Higher

  16. Slide 16: Closed Bore MRI Excellence

    Bi ctosep BORE EXCELLENCE Lr Closed Bore MRI Excellence @ TIME MEDICAL International Ventures ‘AWholly Owned Subsidiary of Hs Fischer MICA, QUIN, NEONA, NEXA and Nova 7T — premium and ultra-high field imaging MICA QUIN NEONA NEXA Nova 7T Energy efficient Helium -free High- Neonatal MRI Premium clini

  17. Slide 17: MRI Screening Portfolio

    BB ScREENING SOLUTIONS SS <a MRI Screening Portfolio @ TIME MEDICAL International Ventures VEGA, VEGA+ and MMIS — purpose-built for stroke, vascular and population screening AWholly Owned Subsidiary of A Fischer = => VEGA VEGA+ A= MMIS C © Stroke Screening — Vascular & Neuro we : Mobile MRI =— es SS

  18. Slide 18: Medharanya Suite & Intraoperative MRI

    BB surcicar INNOVATION SS <a Medharanya Suite & Intraoperative MRI @ TIME MEDICAL International Ventures DRIS, DRIS+ and the integrated neuro-surgical ecosystem ‘AWholly Owned Subsidiary of Zs Fischer DRIS J Operating Room Workflow Intraoperative MRI for real-time surgical * guidance — @ Pre-surgica

  19. Slide 19: CT Imaging Portfolio

    Hct imacine CT Imaging Portfolio Clarion CT family — from 32-slice to wide-bore configurations Clarion CT 32 aa Entry diagnostic Cost-effective, high throughput IN PROGRESS Advanced Technology Enhanced Efficiency High Patient Throughput Long Tube Lifespan Clarion CT 64 Cardiac & oncology imaging IN

  20. Slide 20: Portable X-Ray

    x-ray PORTFOLIO Portable X-Ray Empowering Diagnostics Anytime, Anywhere <——_S Battery-Powered and Portable a ae ; Lightweight design with more than 150 images per a a F ~ charge using a Lithium-lon Polymer Battery. Compact size: W-228mm x D-137mm x H-188mm. Advanced Imaging Technology Versatile Clin

  21. Slide 21: X-Ray Solutions

    x-ray PORTFOLIO 4 X-Ray Solutions @ TIME MEDICAL International Ventures RX series and C-ARM — Al-enabled imaging across emergency, ward and field deployment AWholly Owned Subsidiary of “* Fischer Dn eee RX90 RX706 RX590 RX910 C-ARM Approved: CDSCO, BIS AERB; Approved: CDSCO, BIS AERB; Approved: CDSC

  22. Slide 22: Mammography Solutions

    Hy MAmm™ocrapuy 4 La Mammography Solutions @ TIME MEDICAL International Ventures Navigator series — Al-assisted breast cancer screening and tomosynthesis ‘AWholly Owned Subsidiary of AX Fischer Navigator DR CARE Navigator 3000A Al-assisted screening mammography for primary care and Advanced tomosynt

  23. Slide 23: Integrated Healthcare Ecosystem

    BE TECHNOLOGY PLATFORM Lr Integrated Healthcare Ecosystem One patient, one document — 360° patient journey on a hybrid cloud architecture > Flynn Care Health Lounge ATLAS Digital Community Care MIDAS Al Powered Analytics Integrated Diagnostic Al aw eS Al + Cloud + Data LIVE Dx Clinics 2.0 Population

  24. Slide 24: MIDAS — Unified Al Healthcare Screening Ecosystem

    | HEALTHCARE PLATFORM Lr MIDAS — Unified Al Healthcare Screening Ecosystem An integrated Al-powered platform enabling multi-disciplinary early disease detection through a single screening i} workflow (Ommm | CLINICAL WORKFLOW Oral Health Ad MIDAS Al Screening Platform Multi-Specialty Diagnostics Men

  25. Slide 25: MIDAS — Integrated Al Screening Platform

    BB Al screenine MIDAS — Integrated Al Screening Platform Multi-spectral diagnostic Al Products across eye, oral, mental, cardio-pulmonary, women's health, audiology, diabetes and cancer Cardiovascular Eye Health & Lung Health MIDAS Al Platform Preventive Treatment Molecular Nutraceutical, Wound Heal

  26. Slide 26: Advanced Al-enabled Screening

    | SCREENING DEPTH Lr Our Product Facility & Advanced Al-enabled Screening Six condition-specific Al pathways embedded into the clinical workflow Oral Cancer Breast Cancer | Cervical Screening + . = » Me Smartphone imaging Al density + lesion Colposcopy Al + HPV + Al lesion analysis on =e risk integr

  27. Slide 27: LIVE Dx — Population Screening Platform

    Bp Poputation PLATFORM 4 LIVE Dx — Population Screening Platform Population-scale screening with tele-health, remote monitoring and predictive analytics 2 3 4, 5 Screen Risk Stratify Triage Treat & Monitor VY ; Citizen identity & consent Multi-modal Al screening. Predictive risk scoring Al-driven ro

  28. Slide 28: Clinics 2.0 Platform

    BB Hospital DIGITIZATION Clinics 2.0 Platform Specialty EHR, HIS, practice management, telemedicine, Al insights and device interoperability Specialty EHR Specialty-specific clinical templates Telemedicine ec Integrated video CI os consults & e- = WN prescriptions Registration Consult June 2026 HIS

  29. Slide 29: ATLAS — Al Healthcare Analytics Platform

    Bp Anatytics ATLAS — Al Healthcare Analytics Platform From descriptive to prescriptive — a four-stage analytics maturity engine @ Digital Twin Framework ® Real-World Data Analytics © Al/ML Healthcare Intelligence ai en aS fa a a Descriptive Diagnostic Predictive Prescriptive What happened? Why did i

  30. Slide 30: FlynnCare Healthcare Deployment Model

    Bp ivetemenraTioNn MODELS FlynnCare Healthcare Deployment Model Layered care architecture from primary screening to tertiary intervention Centre of Excellence - Advanced analytics - MIS reports FINN. CARE:PLATFORM - Real World Data for Clinical Research - Big data analytics platform - Encompasses al

  31. Slide 31: NanoMedic — SpinCare Regenerative Skin Technology

    Bi Portrotio COMPANY IN NanoMedic — SpinCare Regenerative Skin Technology World's first portable electrospinning system for direct-to-patient regenerative skin substitute application NanoMedic First-in-class - Wound Care = ° i {AAS » Worla's only portable electrospinning sy: Direct-on-patient Single

  32. Slide 32: Obelab — Portable Brain Imaging Platform

    BB PorTFOLIO COMPANY Lr Obelab — Portable Brain Imaging Platform Functional! near-infrared (fNIRS) and cerebral oximetry devices for research and clinical mental-health care Portfolio Focus O be la b A multi-device platform covering high-resolution fNIRS research systems and clinical cerebral oximet

  33. Slide 33: Nervotec — Contactless Vital Signs Measurement

    Bp PortFOLIO COMPANY \ <a Nervotec — Contactless Vital Signs Measurement Predictive healthcare via a 60-second facial scan — no wearables, no contact, no hardware Nervotec Singapore-headquartered - Al-driven Empowers predictive healthcare — contactless, remote, smartphone-only — capturing vitals and

  34. Slide 34: Nanyang Biologics — Al Drug Discovery Platform

    Hp Portrotio COMPANY SS <a Nanyang Biologics — Al Drug Discovery Platform Next-generation natural-compound drug discovery built on NVIDIA + HPE infrastructure with NTU joint research . . PROPRIETARY LIBRARY OF MILLIONS OF NATURAL DRUG COMPOUNDS Nanyang Biologics Bundled Al software + hardware soluti

  35. Slide 35: Nanyang Biologics — CareViva Nutraceutical Portfolio

    Hp Portrotio COMPANY rN Nanyang Biologics — CareViva Nutraceutical Portfolio Evidence-based, scientifically backed nutraceutical products across oncology, metabolic, liver and cardiovascular health 8 Natural CAneviVA, ‘== Support ecer Tumour protection PROVEN EFFICACY Inhibits tumour growth without

  36. Slide 36: 4T4TB — TB Screening Framework

    Mrs FRAMEWORK Lr» 4T4TB — TB Screening Framework Trace, Test, Treat, Track — an Al-enabled portable X-ray driven workflow Trace Test Treat Track Community case finding + Al Portable X-Ray + Al pre-read + DOTS initiation + adherence Outcome tracking + contact cough analysis sputum testing monitoring

  37. Slide 37: SHIELD — Cancer Screening Framework

    BB cancer FRAMEWORK Lr SHIELD — Cancer Screening Framework Screen, Highlight, Investigate, Empower, Long-term monitoring, Develop Screen Highlight Investigate Empower Long-term Develop @ ee eco BIS = =} A W Population-wide Al Risk-stratify and flag Confirmatory imaging & Patient education & Surveill

  38. Slide 38: Corporate Health Screening

    BB CORPORATE HEALTH Lr Corporate Health Screening Workforce wellness, women's health, mental wellness and ESG-linked healthcare Workforce Wellness Preventive Care Women's Health Mental Wellness ESG-linked Health v 2, 4 6 NY Annual health checks + risk Pathways for hypertension, Breast, cervical, fer

  39. Slide 39: Thank You

    Thank You FMV: Building the world's largest Healthcare Al Solutions Platform. Investor & Strategic Partnership Engagements https://fischermv.com Confidential | © FMV Fischer 2026

Fischer Medical Ventures — Investor Presentation (September 2026) on 6ix